University Hospital Brno

Running trials

• Not yet recruiting

  Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis

  2025-523400-72-00· Phase 2· Vertex Pharmaceuticals Inc.· Source

• Not yet recruiting

  A study to compare heart failure medicines in one combined pill with usual care.

  2026-526510-90-00· Phase 3· Institut De Recherches Internationales Servier IRIS· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure

  NCT07584967· Phase 2· AnaCardio AB· Source

• Recruiting

  Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes

  NCT07672769· Phase 2· Faron Pharmaceuticals Ltd· Source

• Recruiting

  A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease

  2026-525197-19-00· Phase 2· Agomab Spain S.L.U.· Source

• Recruiting

  Phase 3 Study of Investigator Choice of Chemotherapy with or without Zoldonrasib as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma

  2025-524928-21-00· Phase 3· Revolution Medicines Inc.· Source

• Recruiting

  A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

  2026-526654-14-01· Phase 3· Janssen Cilag International· Source

• Recruiting

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· Phase 3· Takeda· Source

• Recruiting

  A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

  NCT07665450· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

  NCT07623200· Phase 3· Incyte Corporation· Source

• Not yet recruiting

  A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants with COPD

  2026-525216-34-00· Phase 2· Expedition Therapeutics Inc.· Source

• Not yet recruiting

  Effect of faecal microbiota transplant on the expression of autism spectrum disorder core symptoms in children – open-label phase II clinical trial (FMT-PAS)

  2025-524673-16-00· Phase 2· Masarykova Univerzita· Source

• Recruiting

  International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

  NCT07476729· Phase 3· Charite University, Berlin, Germany· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

  2025-525105-20-00· Phase 1/2· AbbVie Deutschland GmbH & Co. KG· Source

• Not yet recruiting

  Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.

  2026-525883-17-00· Phase 3· Genmab A/S· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma

  NCT07532265· Phase 2· Kinaset Therapeutics Inc· Source

• Recruiting

  A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis

  NCT07516951· Phase 2· Chiesi Farmaceutici S.p.A.· Source

• Not yet recruiting

  Midwife-led Childbirth Review and Psychological Outcomes in New Parents

  NCT07678801· Charles University, Czech Republic· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

  NCT07630974· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma

  2025-523815-12-00· Phase 3· Janssen Cilag International· Source

• Recruiting

  Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)

  NCT07284602· Phase 3· PureTech· Source

• Recruiting

  Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

  NCT07555938· Phase 3· Hoffmann-La Roche· Source

• Enrolling by invitation

  Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD

  NCT07652294· Phase 2· Spyre Therapeutics, Inc.· Source

• Recruiting

  Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07562152· Phase 3· Immuneering Corporation· Source

• Recruiting

  MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab

  NCT07024706· Phase 2· AstraZeneca· Source

• Recruiting

  A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

  NCT07192952· Phase 3· Bayer· Source

• Not yet recruiting

  A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL

  2024-516570-30-00· Phase 2· Centre Hospitalier De Versailles· Source

• Recruiting

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year

  2025-521590-13-00· Phase 3· Janssen Cilag International· Source

• Recruiting

  A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  NCT07357727· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Orthopedic Procedures and Postoperative Delirium in Older Adults in the Czech Republic

  NCT07432009· Tomas Bata Hospital, Czech Republic· Source

• Recruiting

  ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

  NCT07342478· Phase 3· Newave Pharmaceutical Inc· Source

• Recruiting

  A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT07499232· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

  NCT07225270· Phase 3· Genmab· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

  NCT07299019· Phase 3· Zenas BioPharma (USA), LLC· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

  NCT07067463· Phase 3· Zenas BioPharma (USA), LLC· Source

• Recruiting

  A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma

  NCT07456033· Phase 3· GlaxoSmithKline· Source

• Recruiting

  Maridebart Cafraglutide versus Placebo in Adult Participants with Obstructive Sleep Apnea on Positive Airway Pressure Therapy (MARITIME-OSA-1)

  2025-522703-14-00· Phase 3· Amgen Inc.· Source

• Recruiting

  A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  NCT07318558· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Maridebart Cafraglutide versus Placebo in Adult Participants with Obstructive Sleep Apnea not on Positive Airway Pressure Therapy (MARITIME-OSA-2)

  2025-522699-94-00· Phase 3· Amgen Inc.· Source

• Recruiting

  A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

  NCT07277231· Phase 3· BeOne Medicines· Source

• Recruiting

  A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

  NCT07216703· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

  NCT07325292· Phase 3· Sanofi· Source

• Recruiting

  Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT07222566· Phase 3· Pfizer· Source

• Recruiting

  A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  NCT07222761· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

  NCT07218809· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

  NCT06932562· Phase 3· European Myeloma Network B.V.· Source

• Active, not recruiting

  Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

  NCT07225686· Phase 3· Amgen· Source

Showing 50 of 249.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers20 recruiting
• Multiple myeloma14 recruiting
• Heart failure11 recruiting
• Acute lymphoblastic leukaemia9 recruiting
• Chronic lymphocytic leukaemia9 recruiting
• Crohn's disease7 recruiting
• Ovarian cancer7 recruiting
• Myeloproliferative neoplasms6 recruiting
• Acute myeloid leukaemia5 recruiting
• Obesity5 recruiting
• Lung cancer4 recruiting
• Multiple sclerosis4 recruiting
• Myelodysplastic syndromes4 recruiting
• Pancreatic cancer4 recruiting
• Ulcerative colitis4 recruiting
• Asthma3 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)3 recruiting
• Haemophilia3 recruiting
• Immune thrombocytopenia (ITP)3 recruiting
• Mantle cell lymphoma3 recruiting
• Chronic myeloid leukaemia2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Endometrial cancer2 recruiting
• Follicular lymphoma2 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Myasthenia gravis2 recruiting
• Neuroblastoma2 recruiting
• Obstructive sleep apnoea2 recruiting
• Prostate cancer2 recruiting
• Sarcoma2 recruiting
• Alopecia areata1 recruiting
• Ankylosing spondylitis1 recruiting
• Aortic stenosis1 recruiting
• Atrial fibrillation1 recruiting
• Autism1 recruiting
• Burkitt lymphoma1 recruiting
• Cervical cancer1 recruiting
• Colorectal cancer1 recruiting
• COPD1 recruiting
• Cystic fibrosis1 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Down syndrome1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Head and neck cancer1 recruiting
• High blood pressure1 recruiting
• Kidney cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Closed trials

• Completed

  A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative colitis

  NCT07222189· Phase 2· Sanofi-Aventis Recherche & Developpement· Source

• Completed

  Phase 2b Randomized, Double-Blind Study with Phage for CF Subjects with Pseudomonas Lung Infection

  2024-519856-94-00· Phase 2· Biomx Ltd.· Source

• Active, not recruiting

  A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

  NCT06521567· Phase 1/2· GlaxoSmithKline· Source

• Completed

  A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations

  NCT06529419· Phase 2· AstraZeneca· Source

• Completed

  A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction

  2023-508736-62-00· Phase 2· Cardurion Pharmaceuticals Inc.· Source

• Recruiting

  Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

  NCT06282575· Phase 3· Jazz Pharmaceuticals· Source

• Completed

  A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

  2023-506185-31-00· Phase 2/3· Pliant Therapeutics Inc.· Source

• Active, not recruiting

  A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

  NCT06290128· Phase 3· Sanofi· Source

• Recruiting

  A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

  NCT06056297· Phase 3· X4 Pharmaceuticals· Source

• Completed

  A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure

  NCT06299826· Phase 2· AstraZeneca· Source

• Completed

  A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1

  NCT05870748· Phase 2· Sutro Biopharma Inc.· Source

• Terminated

  REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction

  NCT06237309· Phase 2· Regeneron Pharmaceuticals· Source

• Completed

  A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)

  NCT05813288· Phase 3· Areteia Therapeutics Inc.· Source

• Completed

  Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR

  NCT06130540· Phase 1· Novartis Pharmaceuticals· Source

• Completed

  Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

  NCT06119217· Phase 2· Trishula Therapeutics, Inc.· Source

• Completed

  A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)

  2023-509472-42-00· Phase 3· Celgene International II S.a.r.l.· Source

• Completed

  Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)

  NCT06215586· Phase 2· Cardurion Pharmaceuticals, Inc.· Source

• Completed

  A study to investigate efficacy and safety of OG-6219 twice a day in 3 dose levels compared with Placebo in participants aged 18 to 49 with moderate to severe endometriosis-related pain

  2022-501310-57-00· Phase 2· Organon LLC· Source

• Active, not recruiting

  A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease

  NCT05970172· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Active, not recruiting

  A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

  NCT06105632· Phase 2· Pfizer· Source

• Completed

  Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction

  NCT06017609· Phase 2· Shionogi Inc.· Source

• Completed

  Early Detection of HCV in Injection Drug Users

  NCT06431945· Institute of Health Information and Statistics of the Czech Republic· Source

• Terminated

  IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack

  NCT06139328· Phase 2· Boehringer Ingelheim· Source

• Completed

  Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).

  NCT06264674· Phase 3· Chiesi Farmaceutici S.p.A.· Source

• Completed

  Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy

  2022-502208-64-00· Phase 2· Chiesi Farmaceutici S.p.A.· Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source

• Active, not recruiting

  A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

  NCT06045806· Phase 3· Celgene· Source

• Completed

  A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light-chain amyloidosis (RRLCA)

  2022-502057-33-00· Phase 1/2· Sanofi-Aventis Recherche & Developpement· Source

• Completed

  Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

  2022-502196-31-00· Phase 2/3· Kartos Therapeutics Inc.· Source

• Completed

  A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)

  NCT05952869· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  An 18-month study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa

  2022-502921-16-00· Phase 4· Swedish Orphan Biovitrum AB (publ)· Source

• Completed

  A 24-month study evaluating physical activity and joint health in patients 12 years and older, with severe haemophilia A treated once weekly with efanesoctocog alfa.

  2022-500275-31-00· Phase 3· Swedish Orphan Biovitrum AB (publ)· Source

• Active, not recruiting

  Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

  NCT05740566· Phase 3· Amgen· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma

  NCT05562466· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  A study of efficacy and safety of various treatments in participants with idiopathic pulmonary fibrosis (IPF)

  2023-508729-28-00· Phase 2· Novartis Pharma AG· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

  NCT05742802· Phase 3· AstraZeneca· Source

• Completed

  Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)

  2024-517612-29-00· Phase 4· The Brigham And Women’s Hospital Inc.· Source

• Completed

  A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of PTC857 in Adult Subjects With Amyotrophic Lateral Sclerosis (CARDINALS)

  NCT05349721· Phase 2· PTC Therapeutics Inc.· Source

• Terminated

  A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

  NCT05592275· Phase 2· Eli Lilly and Company· Source

• Completed

  Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 years old) with relapsed or refractory solid tumors (Phase I), and further assess efficacy and safety in patients (12 months – 21 years old) with relapsed or refractory neuroblastoma (Phase II)

  NCT05429502· Phase 1/2· Novartis Pharma AG· Source

• Active, not recruiting

  A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

  NCT05469737· Phase 2/3· Bristol-Myers Squibb· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source

• Active, not recruiting

  Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

  NCT05583227· Phase 3· AstraZeneca· Source

• Completed

  A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

  NCT05560646· Phase 2· Organon and Co· Source

• Active, not recruiting

  A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT05559359· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

  NCT05508867· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Safety and efficacy of allogenic adipose tissue-derived mesenchymal stromal cells in patients with epidermolysis bullosa: Clinical trial phase I/II

  2024-516614-37-00· Phase 1/2· Masarykova Univerzita· Source

• Active, not recruiting

  Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

  NCT05206357· Phase 1· Genmab· Source

• Completed

  Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)

  NCT05388760· Phase 2· LEO Pharma· Source

Showing 50 of 119.

Conditions

Diseases this institution publishes on or runs trials for.

• Multiple myeloma32 works · 38 trials
• Chronic lymphocytic leukaemia20 works · 21 trials
• Chronic myeloid leukaemia16 works · 5 trials
• Haemophilia7 works · 8 trials
• Follicular lymphoma5 works · 6 trials